{"entity":{"id":"nct07205718","kind":"trial","name":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TAK-188 in advanced solid tumours, run by Takeda, now recruiting.","summary":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors is a phase 1/2 interventional study registered as NCT07205718 by Takeda, with 223 participants planned, started 2025-11-19 and due to reach its primary completion in 2028-12-26. Interventions recorded: TAK-188.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07205718","url":"https://clinicaltrials.gov/study/NCT07205718"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07205718","phase":"1/2","setting":"An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Takeda","enrolled":223,"outcomes":[]},"route":"/trials/nct07205718/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}]}}